Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for Adult Female Acne (SAFA)
2018-003630-33Phase 3Unknown
- Sponsor
- University of Southampton
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acne vulgaris comparing Spironolactone plus standard care with Placebo plus standard care (2 arms). Primary endpoint: Acne-QoL symptom subscale score at 12 weeks. Status: unknown.
02
Drugs
spironolactone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on 2018-003630-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003630-33.